Intrexon和合成生物制剂再次合作

Pharmadeals Review Pub Date : 2012-08-14 DOI:10.3833/PDR.V2012I8.1789

Heather Cartwright

{"title":"Intrexon和合成生物制剂再次合作","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I8.1789","DOIUrl":null,"url":null,"abstract":"Synthetic Biologics has partnered with Intrexon for a second time to develop and commercialise monoclonal antibodies for three undisclosed infectious disease indications utilising Intrexon's synthetic biology technologies. In return, Intrexon will receive 3.6 million shares of Synthetic common stock, bringing its ownership position in the company to approximately 18%. Intrexon also stands to gain milestone payments and royalties and the collaboration may be expanded to include up to five additional infectious disease indications.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"82 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intrexon and Synthetic Biologics Collaborate Again\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I8.1789\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Synthetic Biologics has partnered with Intrexon for a second time to develop and commercialise monoclonal antibodies for three undisclosed infectious disease indications utilising Intrexon's synthetic biology technologies. In return, Intrexon will receive 3.6 million shares of Synthetic common stock, bringing its ownership position in the company to approximately 18%. Intrexon also stands to gain milestone payments and royalties and the collaboration may be expanded to include up to five additional infectious disease indications.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"82 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I8.1789\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I8.1789","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

Synthetic Biologics公司与Intrexon公司第二次合作，利用Intrexon公司的合成生物学技术开发和商业化针对三种未公开的传染病适应症的单克隆抗体。作为回报，Intrexon将获得360万股Synthetic普通股，使其在该公司的持股比例达到约18%。Intrexon也将获得里程碑付款和版税，合作可能扩大到包括多达五种额外的传染病适应症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Intrexon and Synthetic Biologics Collaborate Again

Synthetic Biologics has partnered with Intrexon for a second time to develop and commercialise monoclonal antibodies for three undisclosed infectious disease indications utilising Intrexon's synthetic biology technologies. In return, Intrexon will receive 3.6 million shares of Synthetic common stock, bringing its ownership position in the company to approximately 18%. Intrexon also stands to gain milestone payments and royalties and the collaboration may be expanded to include up to five additional infectious disease indications.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量